ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CDK4-selective
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CDK4-selective
7
trial(s) found.
NCT06756932
Advanced
Phase 1
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer (
BGB-21447-102
)
BCL2 inhibitor
+ CDK4 selective inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06465368
Curative
Phase 2
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING (
C4391025
)
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT06257264
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors (
BG-68501-101
)
CDK2 inhibitor
+ CDK4 selective inhibitor
Bladder cancer
Breast cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06120283
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (
BGB-43395-101
)
CDK4 selective inhibitor
Breast cancer
Cancer
HER2-negative breast cancer
HR-positive breast cancer
Non-small cell lung cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2576 - Bowral - Southern Highlands Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05216432
Advanced
Phase 1
Recruiting
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (
RLY-2608-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
selective estrogen receptor degrader
+ CDK4 selective inhibitor
Breast cancer
Endometrial cancer
HER2-negative breast cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT04606446
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors. (
KAT6
)
KAT6 inhibitor
+ CDK4 selective inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06105632
Advanced
Phase 2
Active not recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1) (
C4391022
)
CDK4 selective inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Active not recruiting (1)
Recruitment Country and State
NSW (6)
VIC (6)
QLD (4)
SA (3)
WA (2)
NZ (2)
Phase
Phase 1 (5)
Phase 2 (2)
Trial Type
Advanced (6)
Curative (1)
Cancer Therapy Class
CDK4
100%
CDK4 selective
100%
oestrogen axis
100%
ER
86%
CDK6
29%
BCL2
14%
CDK2
14%
PI3Kalpha
14%
KAT6
14%
mTOR
14%
mTORC1
14%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
3021 - St Albans - Western Health - Sunshine Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2109 - North Ryde - Macquarie University Hospital (2)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3168 - Clayton - Monash Medical Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2576 - Bowral - Southern Highlands Private Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
HER2-negative breast cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Endometrial cancer
Gynaecological cancer
Male genital cancers
Prostate cancer
Urogenital cancer
Non-small cell lung cancer
Bladder cancer
Carcinoma
Gastric cancer
Gastroesophageal cancer
Gastrointestinal cancer
Neuroendocrine carcinoma
Ovarian cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Triple-negative breast cancer
Upper gastrointestinal cancer
HR-positive breast cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy